

REMARKS

Claims 3-4 are pending. Claim 3 has been amended. Applicants respectfully request reconsideration of the rejections.

The specification has been amended to correct the table of oligonucleotides. The columns on far right of the column were inadvertently deleted in the substitute table provided in Applicants response of May 9, 2003. The present amendment rectifies this error. No new matter is added.

Claim 3 has been amended to recite a group of ten oligonucleotides. The oligonucleotides are set forth in the specification as follows:

SEQ ID NO 3	CGTCCATAGCAGCGTCCCG	ILK16345
SEQ ID NO 6	CGGGACTCGGGCTGCAGGA	ILK6446
SEQ ID NO 11	GAGTGAAAATGTCGTCCAT	ILK17557
SEQ ID NO 18	CCACAGCAGAGCGGCCCTC	ILK30486
SEQ ID NO 48	AAGTCCCTGCTCTTCCTTG	ILK86042
SEQ ID NO 49	GCCGGGGACACTCTTCATTG	ILK88061
SEQ ID NO 54	AGTGTGTGATGAGAGTAGG	ILK96749
SEQ ID NO 87	GGCCTGCTGCTTTGGGGAGG	ILK159273
SEQ ID NO 88	GCAACCAGAGGCCTGCTGC	ILK160183
SEQ ID NO 97	GCTGATCCCTCCCATGTTGG	ILK173920

Applicants petitioned for review of the restriction requirement to a single oligonucleotide sequence, the decision on which petition was mailed on June 2, 2005. The decision states that Applicant's request for a reasonable number of nucleotide sequences, "is incomplete, as applicants have not provided a list of 10 sequences to be searched. Applicants must make their own election as per MPEP 818.03(e) and the Office can not determine which ten sequences should be rejoined if such were to occur."

Applicants herein request rejoinder of the ten oligonucleotide sequences set forth above.

Claims 3-4 have been rejected under 35 U.S.C. 101. The claims have been amended in accordance with the Examiner's suggestion to recite an isolated oligonucleotide. Withdrawal of the rejection is requested.

The Office Action states that the sequences set forth in the priority application 60/009,074, filed December 21, 1995 do not disclose the nucleotide sequence set forth in SEQ ID NO:18. Applicants

respectfully submit that the sequences of the present claims are disclosed in the priority application. As discussed in the present specification, for example in originally filed Claim 1, the oligonucleotides set forth in SEQ ID NO:3-SEQ ID NO:99 are complementary to an mRNA encoding human integrin linked kinase.

Such complementary sequences are specifically taught in the priority application. For example, at page 3, lines 18-24 the priority application states "Inhibitors include (1) screens aimed at DNA, RNA or ILK structural components e.g. antisense ILK (i.e. synthetic DNA oligonucleotide comprising the complementary nucleotide sequence of the ILK coding region, designed to specifically target the ILK mRNA complement."

The sequence set forth in SEQ ID NO:18 would not be expected to be present in the sense strand set forth in the sequence listing. However, the complement to SEQ ID NO:18 is provided in the seqlist. One of skill in the art can readily see that SEQ ID NO:18 (which is the anti-sense strand) has the sequence: ccacagcagagcggccctc, of which the reverse complement strand is the sequence gagggccgctctgctgtgg. A search of the ILK sequence provided in the priority applications reveals that this sequence lies at residues 286-307 of SEQ ID NO:1.

In view of the above remarks, Applicants respectfully submit that the present invention is entitled to the claimed priority dates.

Claims 3-4 have been rejected under 35 U.S.C. 102(a) as anticipated by Adams *et al.* (1997), Dedhar *et al.* (1997), or Hillier *et al.* (1997). For the reasons set forth above, Applicants respectfully submit that the present application is entitled to the priority date of December 21, 1995, and thus the cited art is not available under 35 U.S.C. 102(e). In view of the above remarks, withdrawal of the rejection is requested.

Applicants note that claims to integrin-linked kinase anti-sense oligonucleotides are discussed in the attached post-filing document, U.S. Patent no. 6,177,273.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

USSN: 09/925,548

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number KINE-001CIP4.

Date: Dec. 16, 2005

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP
By: Pamela J. Sherwood
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231